Objetivo "Cyclopentylamines are ubiquitous compounds within nature and many pharmaceutical products. Their synthesis can be problematic with length and unselective sequences plaguing them. We aim to overcome this shortcoming by developing a new approach whereby we couple two well known reactions; the Aza-Claisen (or Aza-Cope) rearrangement and the Sakurai allylation.The expected outcomes of this research are a new method which is both rapid and selective for the synthesis of cyclopentylamines. We also intend to achieve the total synthesis of the compound (-)-Altemicidin, a highly substituted cyclopentylamine which exhibits potent antitumor and acaricidal properties. Any compounds produced will be screened against various disease states either here at Queen’s using the Centre for Cancer Research and Cell Biology or with our academic and industrial partners." Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsnatural sciencesbiological sciencescell biologymedical and health sciencesclinical medicineoncology Programa(s) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Tema(s) FP7-PEOPLE-2011-IIF - Marie Curie Action: "International Incoming Fellowships" Convocatoria de propuestas FP7-PEOPLE-2011-IIF Consulte otros proyectos de esta convocatoria Régimen de financiación MC-IIF - International Incoming Fellowships (IIF) Coordinador THE QUEEN'S UNIVERSITY OF BELFAST Aportación de la UE € 209 033,40 Dirección UNIVERSITY ROAD LANYON BUILDING BT7 1NN Belfast Reino Unido Ver en el mapa Región Northern Ireland Northern Ireland Belfast Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Pauline Mccann (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos
